Lbp Am Sa lessened its stake in Cencora, Inc. (NYSE:COR - Free Report) by 17.9% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,767 shares of the company's stock after selling 13,728 shares during the quarter. Lbp Am Sa's holdings in Cencora were worth $18,821,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the stock. Voleon Capital Management LP bought a new stake in Cencora during the first quarter worth $3,111,000. Exchange Traded Concepts LLC lifted its holdings in Cencora by 4.5% during the first quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company's stock worth $307,000 after acquiring an additional 48 shares during the period. Focus Partners Wealth lifted its holdings in Cencora by 25.8% during the first quarter. Focus Partners Wealth now owns 5,715 shares of the company's stock worth $1,589,000 after acquiring an additional 1,171 shares during the period. Fiduciary Alliance LLC bought a new stake in Cencora during the second quarter worth $262,000. Finally, Martin Capital Partners LLC lifted its holdings in Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company's stock worth $1,135,000 after acquiring an additional 2,544 shares during the period. Institutional investors own 97.52% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently commented on COR. Jefferies Financial Group lifted their price target on Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, June 30th. Morgan Stanley set a $330.00 price target on Cencora and gave the stock an "equal weight" rating in a report on Wednesday, July 16th. Finally, Wells Fargo & Company lifted their price target on Cencora from $337.00 to $354.00 and gave the stock an "overweight" rating in a report on Wednesday, August 13th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $311.25.
View Our Latest Analysis on Cencora
Insider Buying and Selling at Cencora
In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $290.00, for a total value of $1,478,130.00. Following the completion of the transaction, the chief executive officer directly owned 39,274 shares in the company, valued at approximately $11,389,460. The trade was a 11.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company's stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,993 shares of company stock valued at $16,292,923. 10.80% of the stock is owned by company insiders.
Cencora Trading Up 1.3%
Shares of COR opened at $312.10 on Wednesday. The business has a 50-day moving average of $293.69 and a 200 day moving average of $289.33. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $312.73. The firm has a market cap of $60.51 billion, a P/E ratio of 32.11, a price-to-earnings-growth ratio of 1.57 and a beta of 0.62. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.
Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. During the same quarter last year, the firm posted $3.34 EPS. The firm's revenue for the quarter was up 8.7% on a year-over-year basis. As a group, research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a $0.55 dividend. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora's payout ratio is 22.63%.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
